Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANUHPHR.NS
Strong BuyPremium GrowerAnuh Pharma Limited · Healthcare · India · $101M · Avg Vol: $180K/d
95
StockRankGet insider-trade alerts
Q
68
V
49
M
83
P/E (TTM)
27.0x
ROE
11.7%
D/E
0.0x
Dividend %
1.6%
COMPANY DESCRIPTION
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-malarial, anti-hypertension, expectorant, anti-diabetics, anti-bacterial, anti-gout, anti asthmatics, quinolones, anti...
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 5.3B | 6.5B | 6.6B | 7.7B | 13.5% | 7.8B |
| EPS (INR) | 3.61 | 5.99 | 2.36 | 4.10 | 4.3% | 3.59 |
| Shares | 100.2M | 100.2M | 100.2M | 100.2M | 0.0% | 100.2M |
| Debt | 9.1M | 26.9M | 108.9M | 0.6M | -59.9% | 0.6M |
| Equity | 2.4B | 2.9B | 3.3B | 3.5B | 13.4% | — |
| Op CF | 539.0M | 129.3M | 371.2M | -30.1M | -17.0% | -30.2M |
| Inv CF | -434.8M | 9.2M | -199.1M | 178.4M | — | — |
| Fin CF | -122.9M | -85.7M | -48.6M | -263.3M | — | — |
Loading 1Y...
PRICE (1Y)+23.7%
SMA 50SMA 200
Close
$1.01
RSI (14)
81.3
52W High
$1.04
From 52W High
1.0%
SCORE BREAKDOWN
Quality
68
ROIC
17.1%87.0
ROE
11.7%75.1
GP/Assets
31.3%66.0
Op. Margin
7.1%56.7
FCF/Assets
-2.0%40.6
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.00x95.7
Current Ratio
2.22x43.0
Value
49
P/E (TTM)
27.0x44.6
EV/EBITDA
12.2x59.5
P/FCF
—N/A
P/B
2.8x49.7
P/S
1.2x79.9
Div Yield
1.6%43.3
Momentum
83
52W High %
97%97.9
RS 6M
33%86.7
SMA 50/200
1.03x63.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
38%68.4
FUNDAMENTALS
Market Cap
$101M
P/E (Forward)
—
Gross Margin
22.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANUHPHR.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANUHPHR.NS | Anuh Pharma Limited(you) | $101M | 95 | Strong Buy |
| AHCL.NS | Anlon Healthcare Limited | $88M | 90 | Strong Buy |
| LINCOLN.NS | Lincoln Pharmaceuticals Limited | $135M | 99 | Strong Buy |
| JAGSNPHARM.NS | Jagsonpal Pharmaceuticals Limited | $165M | 94 | Strong Buy |
| SYNCOMF.NS | Syncom Formulations (India) Limited | $208M | 95 | Strong Buy |
| ALBERTDAVD.NS | Albert David Limited | $51M | 93 | Strong Buy |
| AMANTA.NS | Amanta Healthcare Limited | $83M | 82 | Strong Buy |
| VALIANTLAB.NS | Valiant Laboratories Limited | $65M | 83 | Strong Buy |
| VENUSREM.NS | Venus Remedies Limited | $229M | 99 | Strong Buy |
| WANBURY.NS | Wanbury Limited | $91M | 70 | Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%